Compare · ANGO vs MDLN
ANGO vs MDLN
Side-by-side comparison of AngioDynamics Inc. (ANGO) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANGO and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $58.79B, about 127.5x ANGO ($461.1M).
- Over the past year, ANGO is up 20.4% and MDLN is up 9.8% - ANGO leads by 10.6 points.
- MDLN has been more active in the news (6 items in the past 4 weeks vs 1 for ANGO).
- MDLN has more recent analyst coverage (25 ratings vs 8 for ANGO).
- Company
- AngioDynamics Inc.
- Medline Inc.
- Price
- -
- -
- Market cap
- $461.1M
- $58.79B
- 1M return
- -6.32%
- +1.69%
- 1Y return
- +20.40%
- +9.84%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2004
- 2025
- News (4w)
- 1
- 6
- Recent ratings
- 8
- 25
AngioDynamics Inc.
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides vascular interventions and therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
Latest ANGO
- AngioDynamics Inc. filed SEC Form 8-K: Other Events
- SEC Form 10-Q filed by AngioDynamics Inc.
- AngioDynamics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability
- AngioDynamics to Present at the 25th Annual Needham Virtual Healthcare Conference
- Amendment: SEC Form SCHEDULE 13G/A filed by AngioDynamics Inc.
- AngioDynamics to Report Fiscal 2026 Third Quarter Results on April 2, 2026
- AngioDynamics to Present at the Leerink Partners Global Healthcare Conference
- AngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation Platform
- SEC Form SCHEDULE 13G filed by AngioDynamics Inc.
Latest MDLN
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- SEC Form DEFA14A filed by Medline Inc.
- SEC Form DEF 14A filed by Medline Inc.
- Medline announces first-in-healthcare AI robotics partnership with Symbotic
- Medline to report first quarter 2026 results on May 6, 2026
- Medline launches custom product fulfillment technology called Pick Pack Pro™
- Medline recognizes manufacturing facilities with Golden Cone Safety Award
- Medline receives HIRC Member Choice Awards for supply chain achievement and renews Transparency Badge distinction
- Director Healy Patrick J acquired 577,510 shares, increasing direct ownership by 73% to 1,208,159 units (SEC Form 4)
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,058,524,148 worth of shares (26,131,237 units at $40.51) and disposed of 2,088,086 shares (SEC Form 4)